Aggressive treatment of early rheumatoid arthritis to prevent joint damage

Bulletin on the Rheumatic Diseases

Volumn 47, Issue 8, 1998, Pages 2-7

  Pincus, Theodore ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; AZATHIOPRINE; ETANERCEPT; GLUCOCORTICOID; GOLD DERIVATIVE; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PREDNISONE; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

ARTHROPATHY; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; EXERCISE; FUNCTIONAL DISEASE; HUMAN; IMMUNE RESPONSE; MORTALITY; OCCUPATIONAL THERAPY; PATIENT EDUCATION; PHYSIOTHERAPY; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; WORK DISABILITY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE MANAGEMENT; DISEASE PROGRESSION; HUMANS; METHOTREXATE; PREDNISONE; TIME FACTORS;

EID: 0032455026     PISSN: 00075248     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Pincus T, Callahan LF. Prognostic markers of activity and damage in rheumatoid arthritis: why clinical trials and inception cohort studies indicate more favorable outcomes than studies of patients with established disease. Br J Rheumatol 1995;34:196-9.
2. Pincus T, Fuchs HA, Callahan LF, Nance EP, Kaye JJ. Early radiographic joint space narrowing and erosion and later malalignment in rheumatoid arthritis: a longitudinal analysis. J Rheumatol 1998;25:636-40.
3. Wilske KR, Healey LA. Remodeling the pyramid - a concept whose time has come. J Rheumatol 1989;16:565-7.
4. Pincus T, Callahan LF. The 'side effects' of rheumatoid arthritis: joint destruction, disability and early mortality. Br J Rheumatol 1993;32 Suppl 1:28-37.
5. Callahan LF, Pincus T, Huston JW III, Brooks RH, Nance EP Jr, Kaye JJ. Measures of activity and damage in rheumatoid arthritis: depiction of changes and prediction of mortality over five years. Arthritis Care Res 1997;10: 381-94.
6. Weinblatt ME. Rheumatoid arthritis: treat now, not later! [editorial]. Ann Intern Med 1998;124:773-4.
7. Emery P, Salmon M. Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis 1995:54:944-7.
8. Pincus T, Stein CM, Wolfe F. "No evidence of disease" in rheumatoid arthritis using methotrexate in combination with other drugs: a contemporary goal for rheumatology care? Clin Exp Rheumatol 1997;15:591-6.
9. Wolfe F, Pincus T, Fries JF, US Inception Cohort Group. Use of second line "disease modifying" anti-rheumatic drugs (DMARDs) within 5 months of disease onset by 64% of 750 rheumatoid arthritis patients under care of 142 US rheumatologists: an inception cohort study. Arthritis Rheum 1997;40:S218.
10. Pincus T, Marcum SB, Callahan LF. Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. second-line drugs and prednisone. J Rheumatol 1992:19:1885-94.
11. O'Dell J, Case L. Combination DMARD therapy for rheumatoid arthritis: an apparent universal acceptance [abstract]. Arthritis Rheum 1997;40:S50.
12. Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995; 333: 137-41.
13. O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996:334:1287-91.
14. Yelin E, Meenan R, Nevitt M, Epstein W. Work disability in rheumatoid arthritis: effects of disease, social, and work factors. Ann Intern Med 1980:93:551-6.
15. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984;27:864-72.
16. Pincus T, Wolfe F, Callahan LF. Updating a reassessment of traditional paradigms concerning rheumatoid arthritis. In: Wolfe F, Pincus T, editors. Rheumatoid arthritis: pathogenesis, assessment, outcome, and treatment. New York: Marcel Dekker; 1994. p. 1-74.
17. Fuchs HA, Pincus T. Radiographic damage in rheumatoid arthritis: description by nonlinear models [editorial]. J Rheumatol 1992; 19:1655-8.
18. Wolfe F, Cathey MA. The assessment and prediction of functional disability in rheumatoid arthritis. J Rheumatol 1991;18:1298-1306.
19. Mitchell JM, Burkhauser RV, Pincus T. The importance of age, education, and comorbidity in the substantial earnings losses of individuals with symmetric polyarthritis. Arthritis Rheum 1988;31:348-57.
20. Yelin E, Callahan LF. The economic cost and social and psychological impact of musculoskeletal conditions. Arthritis Rheum 1995; 38:1351-62.
21. Pincus T, Brooks RH, Callahan LF. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med 1994;120:26-34.
22. Fries JF, Williams CA, Morfeld D, Singh G, Sibley J. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum 1996;39: 616-22.
23. van Riel PLCM, van der Heijde DMFM, Nuver-Zwart IH, van de Putte LBA. Radiographic progression in rheumatoid arthritis: results of 3 comparative trials. J Rheumatol 1995;22:1797-9.
24. Pasero G, Priolo F, Marubini E, Fantini F, Ferraccioli G, Magaro M, et al. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin a. Arthritis Rheum 1996;39:1006-15.
25. Weinblatt ME, Maier AL, Fraser PA, Coblyn JS. Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. J Rheumatol 1998; 25:238-42.
26. Kremer JM. Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate:followup after a mean of 13.3 years. Arthritis Rheum 1997;40:984-5.
27. Fries JF. Effectiveness and toxicity considerations in outcome directed therapy in rheumatoid arthritis. J Rheumatol 1996;23 Suppl 44:102-6.
28. Pincus T, Stein CM. Glucocorticoids. In: Kelly WN, Harris ED, Ruddy S, Sledge CB, editors. Textbook of Rheumatology. 5th ed. Philadelphia: W.B. Saunders;1997. p. 787-803.
29. Cash JM, Crofford LJ, Gallucci WT, Sternberg EM, Gold PW, Chrousos GP et al. Pituitary-adrenal axis responsiveness to ovine corticotropin releasing hormone in patients with rheumatoid arthritis treated with low dose prednisone. J Rheumatol 1992;19:1692-6.
30. Boers M, Verhoeven, AC, Markusse, HM, van de Laar MAFJ, Westhovens R, van Denderen et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine in early rheumatoid arthritis. Lancet 1997;350:309-18.
31. Moreland LW, Baumgartner SW, Schiff MH, Tindall E, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-147.
32. Pincus T. Approach to the patient with polyarthritis or generalized musculoskeletal pain. In: Kelley WN, editor. Textbook of internal medicine, 3rd ed. Philadelphia: Lippincott-Raven; 1992. p. 1094-1100.
33. Pincus T, Callahan LF. How many types of patients meet classification criteria for rheumatoid arthritis? [editorial]. J Rheumatol 1994;21:1385-9.
34. Holman HR, Lorig KR. Patient education: essential to good health care for patients with chronic arthritis. Arthritis Rheum 1997;40: 1371-3.